{"product_id":"neurodegeneration-isbn-9781405196932","title":"Neurodegeneration","description":"Most textbooks on neurodegenerative disorders have used a classification scheme based upon either clinical syndromes or anatomical distribution of the pathology.  In contrast, this book looks to the future and uses a classification based upon molecular mechanisms, rather than clinical or anatomical boundaries.  Major advances in molecular genetics and the application of biochemical and immunocytochemical techniques to neurodegenerative disorders have generated this new approach. Throughout most of the current volume, diseases are clustered according to the proteins that accumulate within cells (e.g. tau, α-synuclein and \u003cst1:stockticker w:st=\"on\"\u003eTDP\u003c\/st1:stockticker\u003e-43) and in the extracellular compartments (e.g. β-amyloid and prion proteins) or according to a shared pathogenetic mechanism, such as trinucleotide repeats, that are a feature of specific genetic disorders. Chapters throughout the book conform to a standard lay-out for ease of access by the reader and are written by a panel of International Experts  \u003cp\u003e\u003c\/p\u003e Since the first edition of this book, major advances have been made in the discovery of common molecular mechanisms between many neurodegenerative diseases most notably in the frontotemporal lobar degenerations (FTLD) and motor neuron disease or amyotrophic lateral sclerosis.  \u003cp\u003e\u003c\/p\u003e This book will be essential reading for clinicians, neuropathologists and basic neuroscientists who require the firm up-to-date knowledge of mechanisms, diagnostic pathology and genetics of Neurodegenerative diseases that is required for progress in therapy and management.  List of Contributors, viii  \u003cp\u003ePreface, xii\u003c\/p\u003e \u003cp\u003eList of Abbreviations, xiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 1 Introduction: Basic Mechanisms of Neurodegeneration\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Introduction to Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders, 3\u003cbr\u003e \u003ci\u003eDennis W. Dickson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 Cell Death and Neurodegeneration, 6\u003cbr\u003e \u003ci\u003eVioletta N. Pivtoraiko and Kevin A. Roth\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Oxidative Stress and Balance in Neurodegenerative Diseases, 10\u003cbr\u003e \u003ci\u003eGeorge Perry, Siddhartha Mondragón-Rodríguez, Akihiko Nunomura, Xiongwei Zhu, Paula I. Moreira and Mark A. Smith\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Protein Aggregation in Neurodegeneration, 13\u003cbr\u003e \u003ci\u003eAdriano Aguzzi and Veronika Kana\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Protein Degradation in Neurodegeneration: The Ubiquitin Pathway, 18\u003cbr\u003e \u003ci\u003eLynn Bedford, Robert Layfi eld, Nooshin Rezvani, Simon Paine, James Lowe and R. John Mayer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Genetics of Neurodegeneration, 22\u003cbr\u003e \u003ci\u003eJohn Hardy\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 Transgenic Animal Models of Proteinopathies, 26\u003cbr\u003e \u003ci\u003eNaruhiko Sahara, Heather Melrose, Simon D'Alton and Jada Lewis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 2 Alzheimer's Disease and Aging\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e8 Clinical Aspects of Alzheimer's Disease, 39\u003cbr\u003e \u003ci\u003eDavid Knopman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 Genetics of Alzheimer's Disease, 51\u003cbr\u003e \u003ci\u003eLars Bertram and Rudolph E. Tanzi\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Neuropathology of Alzheimer's Disease and its Variants, 62\u003cbr\u003e \u003ci\u003eCharles Duyckaerts and Dennis Dickson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 Amyloid\u003ci\u003e-\u003c\/i\u003eß Production, 92\u003cbr\u003e \u003ci\u003eColin L. Masters and Konrad Beyreuther\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 Elimination of Amyloid ß from the Brain, its Failure in Alzheimer's Disease and Implications for Therapy, 97\u003cbr\u003e \u003ci\u003eRoy O. Weller, Seth Love and James A.R. Nicoll\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 3 Tauopathies\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e13 Introduction to the Tauopathies, 105\u003cbr\u003e \u003ci\u003eMichel Goedert\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17, 110\u003cbr\u003e \u003ci\u003eBernardino Ghetti, Zbigniew K. Wszolek, Bradley F. Boeve, Salvatore Spina and Michel Goedert\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Progressive Supranuclear Palsy and Corticobasal Degeneration, 135\u003cbr\u003e \u003ci\u003eDennis W. Dickson, Jean-Jaques Hauw, Yves Agid and Irene Litvan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Pick's Disease, 156\u003cbr\u003e \u003ci\u003eDavid G. Munoz, Huw R. Morris and Martin Rossor\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Argyrophilic Grain Disease, 165\u003cbr\u003e \u003ci\u003eMarkus Tolnay and Heiko Braak\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 Parkinsonism–Dementia Complex of Guam, 171\u003cbr\u003e \u003ci\u003eKiyomitsu Oyanagi, Tomoyo Hashimoto and Mineo Yamazaki\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19 Postencephalitic Parkinsonism, 179\u003cbr\u003e \u003ci\u003eKurt A. Jellinger\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 4 Synucleinopathies\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e20 Introduction to a-Synucleinopathies, 191\u003cbr\u003e \u003ci\u003eMaria Grazia Spillantini\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21 Parkinson's Disease, 194\u003cbr\u003e \u003ci\u003eKurt A. Jellinger\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e22 Dementia with Lewy Bodies and Parkinson's Disease Dementia, 224\u003cbr\u003e \u003ci\u003ePaul G. Ince\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e23 Lewy Bodies in Conditions other than Disorders of a-Synuclein, 238\u003cbr\u003e \u003ci\u003eCoro Paisán-Ruiz, Laura Parkkinen and Tamas Revesz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e24 Multiple System Atrophy, 242\u003cbr\u003e \u003ci\u003eJanice L. Holton, Andrew J. Lees and Tamas Revesz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 5 Trinucleotide Repeat Disorders\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e25 Introduction to Trinucleotide Repeat Diseases, 255\u003cbr\u003e \u003ci\u003eH. Brent Clark\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e26 Huntington's Disease, 258\u003cbr\u003e \u003ci\u003eJohn C. Hedreen and Raymund A.C. Roos\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e27 Spinocerebellar Ataxias, 273\u003cbr\u003e \u003ci\u003eHidehiro Mizusawa, H. Brent Clark and Arnulf H. Koeppen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e28 Friedreich's Ataxia, 288\u003cbr\u003e \u003ci\u003eArnulf H. Koeppen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e29 Dentatorubral-pallidoluysian Atrophy, 299\u003cbr\u003e \u003ci\u003eHitoshi Takahashi, Mitsunori Yamada and Shoji Tsuji\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e30 Spinal and Bulbar Muscular Atrophy, 307\u003cbr\u003e \u003ci\u003eGen Sobue, Hiroaki Adachi and Masahisa Katsuno\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 6 Prion Disorders\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e31 Introduction to Prion Disorders, 315\u003cbr\u003e \u003ci\u003eAdriano Aguzzi and Veronika Kana\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e32 Sporadic Creutzfeldt–Jakob Disease, 322\u003cbr\u003e \u003ci\u003eHerbert Budka, Mark W. Head, James W. Ironside, Pierluigi Gambetti, Piero Parchi and Fabrizio Tagliavini\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e33 Genetic Creutzfeldt–Jakob Disease, 336\u003cbr\u003e \u003ci\u003ePiero Parchi, Pierluigi Gambetti and Sabina Capellari\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e34 Fatal Familial and Sporadic Insomnia, 346\u003cbr\u003e \u003ci\u003ePiero Parchi, Sabina Capellari and Pierluigi Gambetti\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e35 A New Prion Disease: Protease-Sensitive Prionopathy, 350\u003cbr\u003e \u003ci\u003ePierluigi Gambetti, Gianfranco Puoti, Qingzhong Kong and Wenquan Zou\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e36 Variant Creutzfeldt–Jakob Disease, 354\u003cbr\u003e \u003ci\u003eJames W. Ironside, Mark W. Head and Robert G. Will\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e37 Gerstmann–Sträussler–Scheinker Disease, 364\u003cbr\u003e \u003ci\u003eBernardino Ghetti, Fabrizio Tagliavini, Gabor G. Kovacs and Pedro Piccardo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e38 Kuru, 378\u003cbr\u003e \u003ci\u003eCatriona Ann McLean\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e39 Iatrogenic Creutzfeldt–Jakob Disease, 381\u003cbr\u003e \u003ci\u003eJames W. Ironside, Richard S.G. Knight and Mark W. Head\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 7 Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis\/Motor Neuron Disease\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e40 Introduction, 389\u003cbr\u003e \u003ci\u003eJames Lowe\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e41 Frontotemporal Lobar Degeneration with TDP-43 Pathology, 393\u003cbr\u003e \u003ci\u003eIan R.A. Mackenzie and Manuela Neumann\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e42 Neuronal Intermediate Filament Inclusion Disease, 404\u003cbr\u003e \u003ci\u003eNigel J. Cairns\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e43 Frontotemporal Lobar Degeneration with FUS Immunoreactive Inclusions, 412\u003cbr\u003e \u003ci\u003eManuela Neumann and Ian R.A. Mackenzie\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e44 Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis and Spinal Muscular Atrophy, 418\u003cbr\u003e \u003ci\u003eMichael J. Strong, Tibor Hortobágyi, Koichi Okamoto and Shinsuke Kato\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 8 Other Neurodegenerative Disorders\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e45 Introduction: Genetic Analysis as a Lumper and Splitter in Neurodegenerative Disease, 437\u003cbr\u003e \u003ci\u003eJohn E. Duda\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e46 Inherited Amyloidoses and Neurodegeneration: Familial British Dementia and Familial Danish Dementia, 439\u003cbr\u003e \u003ci\u003eTamas Revesz, Agueda Rostagno, Gordon Plant, Tammaryn Lashley, Blas Frangione, Jorge Ghiso and Janice L. Holton\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e47 Neurodegeneration with Brain Iron Accumulation, 446\u003cbr\u003e \u003ci\u003eJohn E. Duda and Kurt A. Jellinger\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e48 Familial Encephalopathy with Neuroserpin Inclusion Bodies, 456\u003cbr\u003e \u003ci\u003eRichard L. Davis and George H. Collins\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e49 Hereditary Ferritinopathies, 461\u003cbr\u003e \u003ci\u003eRuben Vidal, Marie Bernadette Delisle, Olivier Rascol and Bernardino Ghetti\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex, 467\u003c\/p\u003e  \u003cp\u003e“Overall, this textbook provides useful and systematic information on the basic mechanisms of neurodegenerative diseases.  It will provide useful for resident trainees, neurologists and pathologists.”  (\u003ci\u003eCanadian Journal of Neurological Sciences\u003c\/i\u003e, 1 November 2012)                   \u003c\/p\u003e  \u003cp\u003eVolume Editor: \u003cstrong\u003eDr. Dennis W. Dickson\u003c\/strong\u003e, Department of Pathology, Neuropathology Laboratory, Mayo Clinic, Jacksonville, Florida, USA.  Most textbooks on neurodegenerative disorders have used a classification scheme based upon either clinical syndromes or anatomical distribution of the pathology.  In contrast, this book looks to the future and uses a classification based upon molecular mechanisms, rather than clinical or anatomical boundaries.  Major advances in molecular genetics and the application of biochemical and immunocytochemical techniques to neurodegenerative disorders have generated this new approach. Throughout most of the current volume, diseases are clustered according to the proteins that accumulate within cells (e.g. tau, α-synuclein and \u003cst1:stockticker w:st=\"on\"\u003eTDP\u003c\/st1:stockticker\u003e-43) and in the extracellular compartments (e.g. β-amyloid and prion proteins) or according to a shared pathogenetic mechanism, such as trinucleotide repeats, that are a feature of specific genetic disorders. Chapters throughout the book conform to a standard lay-out for ease of access by the reader and are written by a panel of International Experts  \u003c\/p\u003e\u003cp\u003e\u003c\/p\u003e Since the first edition of this book, major advances have been made in the discovery of common molecular mechanisms between many neurodegenerative diseases most notably in the frontotemporal lobar degenerations (FTLD) and motor neuron disease or amyotrophic lateral sclerosis.  \u003cp\u003e\u003c\/p\u003e This book will be essential reading for clinicians, neuropathologists and basic neuroscientists who require the firm up-to-date knowledge of mechanisms, diagnostic pathology and genetics of Neurodegenerative diseases that is required for progress in therapy and management.","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47989683028197,"sku":"NP9781405196932","price":324.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781405196932.jpg?v=1761785088","url":"https:\/\/k12savings.com\/es\/products\/neurodegeneration-isbn-9781405196932","provider":"K12savings","version":"1.0","type":"link"}